title: [Comparison of the effect of 2 therapy concepts in the treatment of Pneumocystis carinii pneumonia. Cotrimoxazole for 21 days versus sequential therapy with cotrimoxazole followed by pentamidine inhalation].
abstract: Standard therapy of pneumocystis carinii pneumonia with cotrimoxazole and intravenous pentamidine second line therapy both have a response rate of 75 to 90%. As severe side effects, myelotoxicity and skin reaction have been observed which may occur from treatment day 7 on. In order to prevent such side effects as well as reduce hospitalization times, an open, randomized pilot study was designed. Object of this study was the comparison of efficacy and safety of two different treatment schemes: standard therapy versus sequential treatment. Twelve patients were treated according to study design: five patients with cotrimoxazole only, and seven patients with sequential therapy consisting of cotrimoxazole followed by pentamidine aerosol. All patients were treated for 21 days. Four out of five patients with cotrimoxazole, and two out of seven patients with sequential therapy, were successfully treated and had no pneumocystis carinii pneumonia relapses within four weeks after termination of treatment. Each group had one treatment failure. Four patients under sequential treatment were not evaluable. - In spite of the rather unfavourable preliminary results, the study should be continued. However, patients with secondary opportunistic infections respectively other severe diseases should not be included into the study.
authors.affiliation: Zentrum der Inneren Medizin, Universitätsklinik Frankfurt.
authors.forename: E B
authors.initials: EB
authors.lastname: Helm
authors.forename: S
authors.initials: S
authors.lastname: Staszewski
authors.forename: K
authors.initials: K
authors.lastname: Arasteh
authors.forename: V
authors.initials: V
authors.lastname: Jacobi
authors.forename: R
authors.initials: R
authors.lastname: Mulert
authors.forename: R
authors.initials: R
authors.lastname: Wegner
authors.forename: O
authors.initials: O
authors.lastname: Ottmann
authors.forename: H R
authors.initials: HR
authors.lastname: Brodt
authors.forename: M
authors.initials: M
authors.lastname: L'age
authors.forename: W
authors.initials: W
authors.lastname: Stille
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000188:drug therapy*; D010419:Pentamidine / Q000008:administration & dosage*; D010865:Pilot Projects; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage*
chemical_list: D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
vernacular_title: Wirkungsvergleich zweier Therapiekonzepte zur Behandlung der Pneumocystis-carinii-Pneumonie. Cotrimoxazol für 21 Tage versus Sequenztherapie mit Cotrimoxazol und anschliessender Pentamidin-Inhalation.